Investing.com - Pfizer (NYSE: PFE) reported third quarter EPS of $1.06, $0.44 better than the analyst estimate of $0.62. Revenue for the quarter came in at $17.7B versus the consensus estimate of $14.92B.
Guidance
Pfizer sees FY 2024 EPS of $2.75-$2.95 versus the analyst consensus of $2.65.
Pfizer sees FY 2024 revenue of $61.00B-$64.00B versus the analyst consensus of $61.20B.
Pfizer's stock price closed at $28.86. It is down -5.84% in the last 3 months and down -5.53% in the last 12 months.
Pfizer saw 14 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Pfizer's stock price’s past reactions to earnings here.
According to InvestingPro, Pfizer's Financial Health score is "fair performance".
Check out Pfizer's recent earnings performance, and Pfizer's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar